{"schema_version":"secwatch.filing_event.v1","accession":"0001672688-26-000066","form_type":"8-K","ticker":"ABSI","cik":"0001672688","company_name":"Absci Corp","filed_at":"2026-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.844801+00:00","generated_at":"2026-05-15T09:13:39.358011+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Absci reports Q4 net loss $29.6M, advances ABS-201 trial, appoints new CMO","bullets":["Dosed first three cohorts in SAD portion of Phase 1/2a HEADLINE trial for ABS-201; well-tolerated with favorable emerging safety.","Net loss Q4 2025 $29.6M vs $29.0M prior year; full year net loss $115.2M vs $103.1M.","Cash, equivalents, and marketable securities $144.3M as of Dec 31, 2025; sufficient to fund operations into first half 2028.","Appointed Ransi Somaratne, M.D. (former Vertex SVP) as Chief Medical Officer to lead clinical strategy.","Interim proof-of-concept data for ABS-201 expected H2 2026; Phase 2 endometriosis trial initiation planned Q4 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001672688-26-000066","json":"https://secwatch.observer/filing/0001672688-26-000066.json","markdown":"https://secwatch.observer/filing/0001672688-26-000066.md","text":"https://secwatch.observer/filing/0001672688-26-000066.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672688/000167268826000066/0001672688-26-000066-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672688/000167268826000066/absc-20260324.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:13:39.358011+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}